After developing in pediatric hematology and nephrology, therapeutic apheresis is increasingly used in pediatric neurology despite a sparse level of evidence. There are a few retrospective series with a small number of patients, concerning mainly autoimmune diseases (encephalitis, myasthenia gravis, polyradiculoneuritis). The objective of this work is to study therapeutic apheresis (including plasma exchange and immunoadsorption) among french neuropediatric tertiary centers and to prove that this treatment modality is effective and well tolerated in pediatric neurology diseases.
Multicenter medical data collection : * Montpellier * Toulouse * Bordeaux * Marseille * Nancy * Paris Kremlin Bicêtre * Paris Robert Debré * Paris Necker * Paris Trousseau * Lyon * Besançon * Rennes * Reims * Strasbourg * La Réunion * Nantes * Tours
Study Type
OBSERVATIONAL
Enrollment
200
Efficacy of apheresis
Uh Montpellier
Montpellier, France
global neurological efficacy of therapeutic apheresis as assessed
lobal neurological efficacy of therapeutic apheresis as assessed by modified rankin score Modifed Rankin score, ranging from 0 (no symptoms) to 6 (death)
Time frame: through study completion, an average of 2 years
Incidence of therapeutic apheresis adverse events as assessed
tIncidence of therapeutic apheresis adverse events as assessed by low blood tension rate, transfusion rate, infection rate, hypocalcaemia rate, thrombosis rate, allergy rate, anemia rate, hemostasis disorders rate).
Time frame: through study completion, an average of 2 years
Incidence of adjuvant treatments
Incidence of adjuvant treatments (corticosteroid therapy, immunoglobulins, immunosuppressants),
Time frame: through study completion, an average of 2 years
Incidence of hospitalization in intensive care
Incidence of hospitalization in intensive care, intubation rate
Time frame: through study completion, an average of 2 years
Description of the therapeutic apharesis modalities
number of procedures
Time frame: through study completion, an average of 2 years
Description of the therapeutic apharesis modalities
exchanged volume (in plasma volume percentage) for each procedure
Time frame: through study completion, an average of 2 years
Description of the therapeutic apharesis modalities
type of separation et number of participants with ttt-related advesre events
Time frame: through study completion, an average of 2 years
Description of the therapeutic apharesis modalities
type of replacement solution (isotonic saline, albumin, fresh frozen plasma)
Time frame: through study completion, an average of 2 years
Number of participitants with treatment-related adverse events
rate of arterial hypotension (\< age standards and and requiring isotonic saline bolus, for each patient and for procedure)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of hypocalcemia (ionized calcium \<1,1 mmol/L, for each patient and for each procedure)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of hypoalbuminemiafor for each patient and for each procedure)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of thrombosis (confirmed by a CT scan or ultrasound, for each patient)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of infections related catheter (for each patient)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of allergics reactions (for each patient and for each procedure)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of anemia (Hb \< 7,0 g/dL, for each patient)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of transfusion (for each patient)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of haemostasis disorder (platelets \< 100 \<G/L ; TQ \< 40 % ; fibrinogen \< 1 G/L ; (for each patient and for each procedure)
Time frame: during procedures
Number of participitants with treatment-related adverse events
rate of death
Time frame: during procedures
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.